factor b

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.

Factor B-IN-6 is an orally bioavailable inhibitor of Factor B. It exhibits significant inhibitory activity on the activation of the human serum alternative pathway. In model animals, Factor B-IN-6 can improve kidney lesions and function, reducing urinary protein levels. Factor B-IN-6 is applicable for kidney disease research.

Factor B-IN-7 (Compound (I)) is a selective inhibitor of Factor B. It disrupts the interaction between Factor B and C3b, thereby preventing excessive complement activation. Factor B-IN-7 holds potential for research into complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD).

Factor B-IN-8 (Compound (3R,4R)-15) is a potent, selective, and orally active inhibitor of Factor B, demonstrating an IC50 value of 10.2 nM. It effectively blocks the interaction between Factor B and C3b, thus preventing the formation of the C3 convertase (C3bBb). Additionally, Factor B-IN-8 hinders the deposition of the membrane attack complex (MAC) along the alternative pathway with an IC50 of 59.3 nM. This compound reduces the cleavage of Factor B protein and lessens the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 is applicable in the research of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).

Factor B-IN-1 is a Factor B inhibitor (IC50 = 43 nM) and is an analog of compound 13. It is used to inhibit complement pathway factor B and has improved pharmacokinetic properties (oral availability in rats and dogs).

Factor B-IN-3 is a potent inhibitor of complement factor B. Factor B-IN-3 can be used to study inflammatory and immune-related diseases.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

Factor B-IN-4 is a potent inhibitor (IC50: 1 μM) of complement factor B. Factor B-IN-4 can be used to study inflammatory and immune-related diseases.

Anti-Complement Factor B Antibody is a highly specialized humanized monoclonal antibody target and neutralize complement factor B, inhibition of the alternative complement pathway by disrupting the enzymatic assembly of the C3 convertase complex across various immunological experimental models.

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.

SB-431542 is an inhibitor of ALK5/TGF-β type I Receptor (IC50=94 nM) and is selective. SB 431542 also has inhibitory activity against ALK4 and ALK7 but not other proteins. SB 431542 can be used for induced differentiation of stem cells.

LDN193189 (LDN-193189) (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8/0.8/5.3/16.7 nM for ALK1/2/3/6).

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.

Pirfenidone (AMR69) inhibits the production of CCL2 and CCL12 in fibroblasts and also decreases TGF-β2 protein levels. Pirfenidone is an antifibrotic agent that is commonly used in studies related to pulmonary fibrosis and also has anti-inflammatory activity.

Galunisertib (LY2157299) is a TGF-β receptor type I (TGF-βRI) inhibitor (IC50=56 nM) that is selective. Galunisertib has antitumor activity and can be used in combination with PD-1 inhibitors.

A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.

SRI-011381 hydrochloride, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

RepSox (ALK5 Inhibitor II) is a TGFβR-1/ALK5 inhibitor that selectively inhibits the binding of ATP to ALK5 and the autophosphorylation of ALK5 (IC50=23/4 nM). RepSox induces adipogenesis in MEFs cells.

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

Hydrochlorothiazide (HCTZ) is a Thiazide Diuretic. The physiologic effect of hydrochlorothiazide is by means of Increased Diuresis.

Oxymatrine (Oxysophoridine) is an alkaloid isolated from Sophora flavescens, used as the antibiotic. It is a traditional Chinese medicine used in the treatment against hepatitis B virus.It can also inhibit iNOS expression and TGF - β / Smad pathway.

Alantolactone is a selective inhibitor of STAT3 that induces cancer-associated apoptosis and has antitumor activity.